Economic Daily News : From Dressings to Face Masks! AMS BioteQ Expands into Japanese Market, Creating a New Face for Taiwan's Medical Aesthetics

經濟日報

 

Penetrating Japan's Advanced Wound Care Market: AMS BioteQ's Technological Edge Addresses Elderly Care Needs

 

AMS BioteQ (6864): From Taiwanese Roots to Global Expansion

Originating as a medical dressing manufacturer and now led by Chairman Dr. Tsai Yi-Ju, AMS BioteQ (6864) has systematically built an end-to-end value chain—from R&D and regulatory approvals to cross-border exports and distribution networks. Since securing Japan’s market authorization for its SIPSIP®Foam wound dressings to gaining international recognition for its waterless sheet mask technology, the company is steadily unlocking Asia’s healthcare markets through robust R&D capabilities and asset-light market penetration strategies.

 

AMS BioteQ Team Showcases Global Expertise at Beautyworld Japan.

 

We began exploring Japan’s market in 2019, focusing on elderly care and advanced wound management," recalls Chairman Dr. Tsai Yi-Ju. "During my visit to Medical Japan Expo, the stark contrast between Japanese and Taiwanese market demands became evident. The pandemic reshaped care ecosystems over three years, yet the demand for wound dressings surged unexpectedly."

 

After years of R&D refinement, AMS BioteQ’s SIPSIP®Foam dressing achieved Japan’s medical device certification in 2023. Dr. Tsai notes, "Japan’s dressing market had long been dominated by global giants like Smith & Nephew and Mölnlycke. Taiwanese manufacturers faced near-zero foothold—a challenge starting from scratch. As of 2024, only 24 similar products are certified nationwide, and we’re the sole Taiwanese brand among them."

 

With Japan’s aging population accelerating, chronic wounds (diabetic foot ulcers, pressure injuries, burns) drive urgent demand for high-quality yet affordable solutions. "SIPSIP®Foam is engineered for fragile skin and slow-healing wounds," explains Dr. Tsai. "Its cost-effectiveness and safety precisely address local market gaps."

 

"We don’t just sell products—we deliver holistic solutions," emphasizes Dr. Tsai. "Product quality and pricing must align with seniors’ actual needs and financial realities. Many elderly struggle with pressure sores, ulcers, and thermal injuries. SIPSIP®Foam was developed to be an accessible, clinically effective choice."

 

AMS BioteQ Debuts New Brand Identity at Tokyo Beauty Expo, Drawing Buyer Attention with Innovative Dry Sheet Mask

 

AMS BioteQ Expands into Beauty with Dry Sheet Mask Debut at Beautyworld Japan

 

Beyond medical dressings, AMS BioteQ marked May 2025 by introducing its proprietary dry sheet mask technology at Beautyworld Japan—the country’s premier beauty exhibition. Derived from the SIPSIP® Pro gelatin dressing platform, these masks offer exceptional stability, portable packaging, and optimized preservation for fragile actives like vitamin C and collagen peptides.

 

"We’re not just launching a new mask, but defining a new category—bringing surgical-grade dressing science into daily skincare," emphasized Chairman Dr. Tsai Yi-Ju.

 

The lineup features five targeted formulas (brightening, hydrating, sebum-control, anti-aging, and soothing), with ultra-thin design, high elasticity, and hygienic single-use appeal driving strong buyer interest. Multiple Japanese distributors have initiated talks to introduce the products across Asia—leveraging Japan’s reputation for quality as a springboard into India, Thailand, and Singapore.

 

AMS BioteQ’s Revolutionary Dry Sheet Masks Redefine Daily Skincare with Surgical-Grade Innovation

 

Showcasing a breakthrough fusion of medical expertise and cosmetic science, AMS BioteQ’s dry sheet masks—weighing just 10g versus conventional 30g wet masks—are capturing global buyer attention with their compact design, extended shelf life, and logistics efficiency. These advantages position them as ideal solutions for travel retail, post-procedure care, and sustainable beauty.

 

Currently, AMS BioteQ is actively expanding into the Japanese market, seeking collaborations with local distribution channels to secure shelf space in well-known drugstore chains, fully entering the OTC market, and engaging in discussions with several influential brands and distributors to further deepen market integration and product feasibility.

 

At the exhibition, AMS Biotech enthusiastically engaged with Japanese buyers, actively expanding its Asian market presence and promoting Taiwan's innovative beauty technologies.

 

Strategic Differentiation: A Global Expansion Anchored in Taiwan

 

For the Middle East market, AMS adopts a distributor-led approach, participating in government medical tenders to integrate into the public healthcare system—complementing its drugstore-focused strategy in Japan. "Each market demands tailored tactics, but our core remains unchanged: leveraging Taiwanese technology to create what the world truly needs," said Dr. Tsai Yi-Ju.

 

"We aim not to be the largest, but the most precise and effective," emphasized Chairman Tsai. From medical dressings to dry sheet masks, from elderly care to daily skincare, AMS is scripting a new chapter for Taiwan’s biotech industry on the global stage through unique technological evolution and international resonance.